Densitometry in glucocorticoid-induced osteoporosis.
Bone density measurement is a critical tool in the management of glucocorticoid-induced osteoporosis (GIOP). This review addresses the utility of various measurement devices (dual-energy X-ray absorptiometry [DXA], quantitative ultrasound [QUS], quantitative CAT scanning [QCT]), their role in monitoring changes in bone mineral density (BMD), and the relationship of BMD and fracture risk in GIOP. A higher BMD threshold should be utilized for estimating fracture risk in patients on glucocorticoids.
Maricic
Michael
M
Southern Arizona VA Health Care System, Tucson, AZ 85723, USA. mikecaricic@msn.com
Gluck
Oscar
O
D015502:Absorptiometry, Photon; D015519:Bone Density / Q000187:drug effects; D050723:Fractures, Bone / Q000209:etiology; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000175:diagnosis*; D012307:Risk Factors
D005938:Glucocorticoids